New Filings At The EMA
New medicines under evaluation at the European Medicines Agency.
You may also be interested in...
The European Medicines Agency is this week considering applications from two companies seeking the coveted accelerated assessment review pathway for their new products.
In 2018, the European Medicines Agency considered 24 requests from drug companies for fast-track review of their planned marketing authorization applications. The agency has granted at least nine requests, eleven have been rejected and the results of four have yet to be disclosed.
Three companies are set to learn this week whether the European Medicines Agency will fast track its review of their soon-to-be-filed EU marketing applications.